RDC-0313 + Buprenorphine + Placebo
Phase 1Completed 0 watching 0 views this week💤 Quiet
30
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Substance-Related Disorders
Conditions
Substance-Related Disorders
Trial Timeline
Jan 1, 2010 → Jul 1, 2010
NCT ID
NCT01046539About RDC-0313 + Buprenorphine + Placebo
RDC-0313 + Buprenorphine + Placebo is a phase 1 stage product being developed by Alkermes for Substance-Related Disorders. The current trial status is completed. This product is registered under clinical trial identifier NCT01046539. Target conditions include Substance-Related Disorders.
Hype Score Breakdown
Clinical
10
Activity
5
Company
7
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01046539 | Phase 1 | Completed |
Competing Products
1 competing product in Substance-Related Disorders
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| naltrexone for extended release injectable suspension | Alkermes | Approved | 82 |